JP2010528047A5 - - Google Patents

Download PDF

Info

Publication number
JP2010528047A5
JP2010528047A5 JP2010509554A JP2010509554A JP2010528047A5 JP 2010528047 A5 JP2010528047 A5 JP 2010528047A5 JP 2010509554 A JP2010509554 A JP 2010509554A JP 2010509554 A JP2010509554 A JP 2010509554A JP 2010528047 A5 JP2010528047 A5 JP 2010528047A5
Authority
JP
Japan
Prior art keywords
composition
antibody
factor
antagonist
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010509554A
Other languages
English (en)
Japanese (ja)
Other versions
JP5416695B2 (ja
JP2010528047A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/064526 external-priority patent/WO2008147883A1/en
Publication of JP2010528047A publication Critical patent/JP2010528047A/ja
Publication of JP2010528047A5 publication Critical patent/JP2010528047A5/ja
Application granted granted Critical
Publication of JP5416695B2 publication Critical patent/JP5416695B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010509554A 2007-05-23 2008-05-22 補体が関係している眼の状態の予防および治療 Expired - Fee Related JP5416695B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
US60/939,791 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013236445A Division JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療

Publications (3)

Publication Number Publication Date
JP2010528047A JP2010528047A (ja) 2010-08-19
JP2010528047A5 true JP2010528047A5 (enExample) 2012-05-10
JP5416695B2 JP5416695B2 (ja) 2014-02-12

Family

ID=39638868

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010509554A Expired - Fee Related JP5416695B2 (ja) 2007-05-23 2008-05-22 補体が関係している眼の状態の予防および治療
JP2013236445A Withdrawn JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療
JP2016015288A Withdrawn JP2016145205A (ja) 2007-05-23 2016-01-29 補体が関係している眼の状態の予防および治療
JP2017146477A Pending JP2017197577A (ja) 2007-05-23 2017-07-28 補体が関係している眼の状態の予防および治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013236445A Withdrawn JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療
JP2016015288A Withdrawn JP2016145205A (ja) 2007-05-23 2016-01-29 補体が関係している眼の状態の予防および治療
JP2017146477A Pending JP2017197577A (ja) 2007-05-23 2017-07-28 補体が関係している眼の状態の予防および治療

Country Status (28)

Country Link
US (6) US8007791B2 (enExample)
EP (1) EP2152755B1 (enExample)
JP (4) JP5416695B2 (enExample)
KR (1) KR101540126B1 (enExample)
CN (3) CN104367999A (enExample)
AR (1) AR066660A1 (enExample)
AU (1) AU2008256835B2 (enExample)
BR (1) BRPI0811142A8 (enExample)
CA (1) CA2683498A1 (enExample)
CL (1) CL2008001498A1 (enExample)
CY (1) CY1116062T1 (enExample)
DK (1) DK2152755T3 (enExample)
ES (1) ES2533242T3 (enExample)
HK (1) HK1207327A1 (enExample)
HR (1) HRP20150281T1 (enExample)
IL (2) IL201476A (enExample)
MX (1) MX2009012422A (enExample)
PE (1) PE20090294A1 (enExample)
PH (1) PH12013500992B1 (enExample)
PL (1) PL2152755T3 (enExample)
PT (1) PT2152755E (enExample)
RS (1) RS53901B1 (enExample)
RU (2) RU2522976C2 (enExample)
SG (1) SG10201401404RA (enExample)
SI (1) SI2152755T1 (enExample)
TW (2) TWI419704B (enExample)
WO (1) WO2008147883A1 (enExample)
ZA (1) ZA200907028B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4764590B2 (ja) * 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP5564045B2 (ja) * 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
CA2761310C (en) * 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
BR112013010769A2 (pt) 2010-11-01 2019-09-24 Genentech Inc predição de progressão para degeneração macular relacionada à idade avançada usando um escore poligênico
PT2661433T (pt) 2011-01-04 2017-10-24 Novartis Ag Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
CA2882724A1 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
WO2015054298A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
US20160339008A1 (en) * 2013-10-25 2016-11-24 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
JP6853257B2 (ja) * 2015-09-23 2021-03-31 サンガモ セラピューティクス， インコーポレイテッド Ｈｔｔリプレッサー及びその使用
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CN108513585A (zh) 2015-10-30 2018-09-07 豪夫迈·罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
MY196448A (en) 2015-10-30 2023-04-12 Genentech Inc Anti-Htra1 Antibodies and Methods of use Thereof
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
KR20180091097A (ko) * 2015-12-23 2018-08-14 그리노파티온 바이오테크 게엠베하 보체 활성화를 억제하기 위한 폴리펩티드
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018217720A1 (en) * 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009778A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods for culturing mesenchymal stem cells, products thereof, and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ATE410512T1 (de) 1997-11-21 2008-10-15 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
JP4437192B2 (ja) * 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
CA2348757A1 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000037025A2 (en) * 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
ES2327785T3 (es) 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4836329B2 (ja) 1999-03-11 2011-12-14 メルク セローノ エス．エイ． 血管接着分子およびその機能の調節
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMANE SECRETIED PROTEINS
CA2491433A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
TW201716437A (zh) * 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Similar Documents

Publication Publication Date Title
JP2010528047A5 (enExample)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP7695187B2 (ja) ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
US20220162296A1 (en) Personalized treatment of ophthalmologic diseases
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2011504872A5 (enExample)
JP5990511B2 (ja) 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体
JP2016504416A5 (enExample)
JP2020535184A5 (enExample)
RU2008144802A (ru) Применение антител против ил-1 для лечения глазных расстройств
JP2017535285A5 (enExample)
JP2014532072A5 (enExample)
JP2017502023A (ja) 眼疾患を治療する組成物および方法
JP2015503909A5 (enExample)
EP2200699A1 (en) Antigen binding proteins
JP2011503094A5 (enExample)
JP2021520195A5 (enExample)
JP2018530574A5 (enExample)
RU2018103960A (ru) Антитела против ang-2, содержащие только тяжелую цепь
JP2018527327A5 (enExample)
JP2025114621A (ja) 神経変性疾患を治療するための改変抗ｐｄ－ｌ１抗体および治療方法および使用
TW202237181A (zh) 治療眼部疾病之方法
JP2018523673A5 (enExample)
JP7382343B2 (ja) Ｍｆａｐ４に対する抗体